BIO 2026: Montara is trying to open more CNS treatment possibilities by using one drug that blocks a target-specific drug’s activity in the periphery in combo with a brain active and concentrated one

1 day ago
1 min read

CEO Nicholas Hertz describes this approach, which was recently made famous through the success of Karuna. Andrew Miller, a founder of Karuna, recently joined Montara's board.

https://vimeo.com/1203673249

Coverage brought to you by

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

BIO 2026: Montara is trying to open more CNS treatment possibilities by using one drug that blocks a target-specific drug’s activity in the periphery in combo with a brain active and concentrated one

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight